Healthcare

HB 755 requires health insurers in Pennsylvania (excluding grandfathered plans) to cover all preventive health services listed by the Insurance Department without cost-sharing, such as copays or deductibles. This directly affects insurers who must comply with the coverage rules and enrollees who gain access to preventive care like vaccinations and screenings at no extra cost. The bill empowers the Insurance Department to create and update the preventive services list through a public comment process (15+ business days) and enforce compliance with penalties for violations. It aligns with federal preventive care standards but allows Pennsylvania to adjust the list based on public input and evidence-based guidelines.

HB 404 amends Pennsylvania's Insurance Company Law to extend health insurance coverage for children under family policies. It requires policies to cover dependent children up to age 26 (previously 19) and prohibits insurers from denying or restricting coverage based on a child's financial dependency, residency, marital status, school enrollment, or employment. The bill also allows group health plans to extend coverage for adult children up to age 29 if they meet specific conditions, such as not being married, having no dependents, and residing in Pennsylvania or attending school full-time. This affects all health insurance policies sold in Pennsylvania that provide dependent child coverage.

HB 111 prohibits life insurance companies in Pennsylvania from denying coverage, limiting benefits, or charging higher rates to applicants or policyholders solely because they have been prescribed an opioid overdose reversal agent (like naloxone). The bill directly affects individuals who use these medications, including those with opioid use disorder or at risk of overdose. It defines "adverse action" to include these discriminatory practices and makes such actions violations of existing laws against unfair insurance practices. The law takes effect 60 days after enactment.

HB 33 amends Pennsylvania's Medical Marijuana Act to clarify definitions and strengthen oversight of testing labs and practitioners. It defines key terms like "independent laboratory" (requiring no ties to marijuana businesses) and "approved laboratory" (testing medical marijuana samples under department approval). The bill gives the Department of Health new authority to impose conditions on medical practitioners, such as limiting certifications or requiring supervision, to protect patient safety. These changes directly affect medical marijuana patients, healthcare providers who certify them, and labs testing products for quality and safety. The updates aim to improve accountability in the program through clearer rules for lab accreditation and practitioner oversight.